CBX - China Biotech XYZ

 Due to the pharmaceutical industry's cold spell, an increasing number of enterprises are facing insufficient cash flow to support a multitude of clinical trials. Consequently, there is a rising trend of termination of clinical trials. It is well-known that the collaboration between CTTQ and Wuxi Apptec is very close.  Here we summarize the clinical trials terminated or suspended by Chia Tai-Tianqing: 1.  TQB3015 for cancer: ATR inhibitor CTR20233919: phase 1 trial suspended without explanation Initiated in 2023.12.05, suspended in 2023.12.19 2. TQC3564 for asthma: CRTH2 antagonist CTR20220230: phase 1b study terminated as strategy adjustment Initiated in 2022.1.29, terminated in 2023.5.9 3.  TQC3564  for allergic rhinitis :  CRTH2  antagonist CTR20220964: phase 1b study terminated as strategy adjustment Initiated in 2022.8.17, terminated in 2023.5.9 4.  TQB3823 for cancer: PARP  inhibitor CTR20211789: phase 1 trial terminated as strategy adjustment Initiated in 2021.9.14, te